These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28966273)

  • 1. Synthesis, Docking Simulation, Biological Evaluations and 3D-QSAR Study of 1,4-Dihydropyridines as Calcium Channel Blockers.
    El-Moselhy TF; Sidhom PA; Esmat EA; El-Mahdy NA
    Chem Pharm Bull (Tokyo); 2017; 65(10):893-903. PubMed ID: 28966273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis, Evaluation of Pharmacological Activity, and Molecular Docking of 1,4-Dihydropyridines as Calcium Antagonists.
    Shaldam MA; El-Hamamsy MH; Saleh DO; El-Moselhy TF
    Chem Pharm Bull (Tokyo); 2016; 64(4):297-304. PubMed ID: 26822207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, study of 3D structures, and pharmacological activities of lipophilic nitroimidazolyl-1,4-dihydropyridines as calcium channel antagonist.
    Miri R; Javidnia K; Sarkarzadeh H; Hemmateenejad B
    Bioorg Med Chem; 2006 Jul; 14(14):4842-9. PubMed ID: 16603367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of new 1,4-dihydropyridines containing 4(5)-chloro-5(4)-imidazolyl substituent as a novel calcium channel blocker.
    Iman M; Davood A; Nematollahi AR; Dehpoor AR; Shafiee A
    Arch Pharm Res; 2011 Sep; 34(9):1417-26. PubMed ID: 21975802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding mechanism investigations guiding the synthesis of novel condensed 1,4-dihydropyridine derivatives with L-/T-type calcium channel blocking activity.
    Schaller D; Gündüz MG; Zhang FX; Zamponi GW; Wolber G
    Eur J Med Chem; 2018 Jul; 155():1-12. PubMed ID: 29843108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
    Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
    Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative structure-activity relationship studies on some series of calcium channel blockers.
    Gupta SP; Veerman A; Bagaria P
    Mol Divers; 2004; 8(4):357-63. PubMed ID: 15612639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4,5-dichloroimidazolyl substituents.
    Hosseini M; Miri R; Amini M; Mirkhani H; Hemmateenejad B; Ghodsi S; Alipour E; Shafiee A
    Arch Pharm (Weinheim); 2007 Oct; 340(10):549-56. PubMed ID: 17849444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing dichloroimidazolyl substituents.
    Amini M; Golabchifar AA; Dehpour AR; Pirali HM; Shafiee A
    Arzneimittelforschung; 2002; 52(1):21-6. PubMed ID: 11838270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative QSAR studies of two series of 1,4-dihydropyridines as slow calcium channel blockers.
    Wikel JH; Bemis KG; Kurz K; Denney ML; Main BW; Moore RA; Smith T; Shingleton L; Holland DR
    Drug Des Discov; 1994 Jan; 11(1):1-14. PubMed ID: 8068815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorinated dihydropyridines as candidates to block L-type voltage-dependent calcium channels.
    Menezes Spadeto JP; Freitas MP; Cormanich RA
    J Biomol Struct Dyn; 2022; 40(24):13456-13471. PubMed ID: 34720037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine).
    Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M
    Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies directed toward ascertaining the active conformation of 1,4-dihydropyridine calcium entry blockers.
    Rovnyak G; Andersen N; Gougoutas J; Hedberg A; Kimball SD; Malley M; Moreland S; Porubcan M; Pudzianowski A
    J Med Chem; 1988 May; 31(5):936-44. PubMed ID: 2834556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural Basis of the Modulation of the Voltage-Gated Calcium Ion Channel Ca
    Gao S; Yan N
    Angew Chem Int Ed Engl; 2021 Feb; 60(6):3131-3137. PubMed ID: 33125829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and pharmacological evaluation of pyrimidobenzothiazole-3-carboxylate derivatives as selective L-type calcium channel blockers.
    Chikhale R; Thorat S; Pant A; Jadhav A; Thatipamula KC; Bansode R; Bhargavi G; Karodia N; Rajasekharan MV; Paradkar A; Khedekar P
    Bioorg Med Chem; 2015 Oct; 23(20):6689-713. PubMed ID: 26385444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing lipophilic 4-imidazolyl substituents.
    Navidpour L; Miri R; Shafiee A
    Arzneimittelforschung; 2004; 54(9):499-504. PubMed ID: 15500195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular tools for the study of calcium channels: synthesis and evaluation of biological activity of new derivatives of 4-aryl-1,4-dihydropyridine groups].
    Soldatov NM
    Biokhimiia; 1988 Jul; 53(7):1059-68. PubMed ID: 2846077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities.
    Di Stilo A; Visentin S; Cena C; Gasco AM; Ermondi G; Gasco A
    J Med Chem; 1998 Dec; 41(27):5393-401. PubMed ID: 9876109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and smooth muscle calcium channel effects of dialkyl 1,4-dihydro-2,6-dimethyl-4-aryl-3,5-pyridinedicarboxylates containing a nitrone moiety in the 4-aryl substituent.
    Anana RD; Ng H; Howlett SE; Knaus EE
    Arch Pharm (Weinheim); 1997 Mar; 330(3):53-8. PubMed ID: 9167447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent.
    Mollazadeh S; Shamsara J; Iman M; Hadizadeh F
    Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.